Try a new search

Format these results:

Searched for:

in-biosketch:true

person:mdk230

Total Results:

129


A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Mundi, Prabhjot S; Dela Cruz, Filemon S; Grunn, Adina; Diolaiti, Daniel; Mauguen, Audrey; Rainey, Allison R; Guillan, Kristina; Siddiquee, Armaan; You, Daoqi; Realubit, Ronald; Karan, Charles; Ortiz, Michael V; Douglass, Eugene F; Accordino, Melissa; Mistretta, Suzanne; Brogan, Frances; Bruce, Jeffrey N; Caescu, Cristina I; Carvajal, Richard D; Crew, Katherine D; Decastro, Guarionex; Heaney, Mark; Henick, Brian S; Hershman, Dawn L; Hou, June Y; Iwamoto, Fabio M; Jurcic, Joseph G; Kiran, Ravi P; Kluger, Michael D; Kreisl, Teri; Lamanna, Nicole; Lassman, Andrew B; Lim, Emerson A; Manji, Gulam A; McKhann, Guy M; McKiernan, James M; Neugut, Alfred I; Olive, Kenneth P; Rosenblat, Todd; Schwartz, Gary K; Shu, Catherine A; Sisti, Michael B; Tergas, Ana; Vattakalam, Reena M; Welch, Mary; Wenske, Sven; Wright, Jason D; Canoll, Peter; Hibshoosh, Hanina; Kalinsky, Kevin; Aburi, Mahalaxmi; Sims, Peter A; Alvarez, Mariano J; Kung, Andrew L; Califano, Andrea
UNLABELLED:Predicting in vivo response to antineoplastics remains an elusive challenge. We performed a first-of-kind evaluation of two transcriptome-based precision cancer medicine methodologies to predict tumor sensitivity to a comprehensive repertoire of clinically relevant oncology drugs, whose mechanism of action we experimentally assessed in cognate cell lines. We enrolled patients with histologically distinct, poor-prognosis malignancies who had progressed on multiple therapies, and developed low-passage, patient-derived xenograft models that were used to validate 35 patient-specific drug predictions. Both OncoTarget, which identifies high-affinity inhibitors of individual master regulator (MR) proteins, and OncoTreat, which identifies drugs that invert the transcriptional activity of hyperconnected MR modules, produced highly significant 30-day disease control rates (68% and 91%, respectively). Moreover, of 18 OncoTreat-predicted drugs, 15 induced the predicted MR-module activity inversion in vivo. Predicted drugs significantly outperformed antineoplastic drugs selected as unpredicted controls, suggesting these methods may substantively complement existing precision cancer medicine approaches, as also illustrated by a case study. SIGNIFICANCE:Complementary precision cancer medicine paradigms are needed to broaden the clinical benefit realized through genetic profiling and immunotherapy. In this first-in-class application, we introduce two transcriptome-based tumor-agnostic systems biology tools to predict drug response in vivo. OncoTarget and OncoTreat are scalable for the design of basket and umbrella clinical trials. This article is highlighted in the In This Issue feature, p. 1275.
PMCID:10239356
PMID: 37061969
ISSN: 2159-8290
CID: 5786922

Contemporary practice and perception of autologous blood salvage in hepato-pancreatico-biliary operations: an international survey

Thomas, Alexander S; Belli, Andrea; Salceda, Juan; López-Ben, Santiago; Lee, Ser Y; Kwon, Wooil; Pawlik, Timothy M; Kluger, Michael D
BACKGROUND:This study aimed to assess contemporary knowledge, attitudes and behaviors around transfusion of intraoperative salvaged blood (sRBCt) during hepato-pancreatico-biliary (HPB) operations. Findings are meant to inform the design of future studies that address provider concerns to change behaviors and improve patient outcomes. METHODS:A survey was designed and assessed for relevance, readability and content, and distributed to an international audience of surgeons performing HPB operations. RESULTS:The 237 respondents were predominantly distributed across North America (37.55%), Europe (27.43%) and Asia (19.83%). Roughly one-half (52.74%) of respondents had used sRBCt in HPB surgery before. Transplantation surgeons were more likely than HPB surgeons to have previously used sRBCt [odds ratio = 5.18 (95% CI 1.89-14.20)]. More respondents believed sRBCt was safe for non-cancer versus cancer operations (68.57% vs. 24.17%, p < 0.0001). Less than half (45.71%) of respondents believed that sRBCt was safe in clean-contaminated fields. Most did not utilize preoperative strategies to avoid donor transfusion. CONCLUSION:Practices related to sRBCt in HPB operations vary widely and there is no consensus on its use. Concerns seem primarily related to cancer-specific and infectious outcomes. While further studies are pursued, surgeons may increase their utilization of preoperative strategies to boost hemoglobin levels for at risk patients.
PMID: 37117066
ISSN: 1477-2574
CID: 5786932

Associations Between Patient Characteristics and Whipple Procedure Outcomes Before and After Implementation of an Enhanced Recovery After Surgery Protocol

Koerner, Anna S; Thomas, Alexander S; Chabot, John A; Kluger, Michael D; Sugahara, Kazuki N; Schrope, Beth A
PURPOSE:The Enhanced Recovery After Surgery (ERAS) protocol is a multimodal perioperative care bundle aimed to improve pancreatic surgery outcomes. This work evaluates whether a Whipple ERAS protocol can be safely implemented at a quaternary care center. We also aimed to assess if race and socioeconomic factors are associated with disparities in outcomes in patients undergoing a Whipple ERAS protocol. METHODS:A retrospective review identified demographic and clinical data for 458 patients undergoing pancreaticoduodenectomies (PDs) at a single institution from October 2017 to May 2022. Patients were split into two cohorts: pre-ERAS (treated before implementation) and ERAS (treated after). Outcomes included length of stay (LOS), 30-day readmission and mortality rates, and major complications. RESULTS:There were 213 pre-ERAS PD patients, and 245 were managed with an ERAS protocol. More ERAS patients had a BMI > 30 (15.5% vs. 8.0%; p = 0.01) and received neoadjuvant chemotherapy (15.5% vs. 4.2%; p < 0.001). ERAS patients had a higher rate of major complications (57.6% vs. 37.6%; p < 0.001). Medicaid patients did not have more complications or longer LOS compared to non-Medicaid patients. On univariate analysis, race/ethnicity or gender was not significantly associated with a higher rate of major complications or prolonged LOS. CONCLUSION:A Whipple ERAS protocol did not significantly change LOS, readmissions, or 30-day mortality. Rate of overall complications did not significantly change after implementation, but rate of major complications increased. These outcomes were not significantly impacted by race/ethnicity, gender, tumor staging, or insurance status.
PMID: 37165160
ISSN: 1873-4626
CID: 5786942

Innovation in the Surgical Management of Pancreatic Cystic Neoplasms: Same Operations, Narrower Indications, and an Individualized Approach to Decision-Making

Schleimer, Lauren E; Chabot, John A; Kluger, Michael D
Historically, the management of pancreatic cystic neoplasms (PCN) has been operative. Early intervention for premalignant lesions, including intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN), offers an opportunity to prevent pancreatic cancer-with potential decrement to patients' short-term and long-term health. The operations performed have remained fundamentally the same, with most patients undergoing pancreatoduodenectomy or distal pancreatectomy using oncologic principles. The role of parenchymal-sparing resection and total pancreatectomy remains controversial. We review innovations in the surgical management of PCN, focusing on the evolution of evidence-based guidelines, short-term and long-term outcomes, and individualized risk-benefit assessment.
PMID: 37245941
ISSN: 1558-1950
CID: 5786952

Reconsidering the absence of extrapancreatic extension in T staging for pancreatic adenocarcinoma in the AJCC (8th ed) Staging Manual using the National Cancer Database

Lee, Mirang; Thomas, Alexander S; Lee, Seung Yeoun; Cho, Young Jae; Jung, Hye-Sol; Yun, Won-Gun; Han, Youngmin; Jang, Jin-Young; Kluger, Michael D; Kwon, Wooil
PURPOSE:Although the concept of extrapancreatic extension (EPEx) was removed in the eighth edition of the American Joint Committee on Cancer pancreatic cancer staging system, several studies have supported the prognostic significance of EPEx. This study aimed to investigate the significance of EPEx in pancreatic ductal adenocarcinoma (PDAC) using the National Cancer Database (NCDB). METHODS:Data of patients who underwent resection for PDAC between 2006 and 2016 were extracted and analyzed from the NCDB. Cases arising from premalignant lesions, those with metastases, and those treated with neoadjuvant therapy were excluded. RESULTS:Among 37,634 patients, the median overall survival was 23 months and the 5-year survival rate was 22.7%. The EPEx prevalence was the lowest for T1 stage (63.2%) and increased with each T-stage (T2:83.4%, T3:85.8%). The overall survival was better in EPEx-negative patients than in EPEx-positive patients (median 33.7 vs. 21.5 months; p<0.001). When the T-stages were stratified by EPEx, EPEx-positive patients showed worse survival in all T-stages than EPEx-negative patients. Survival was comparable between T1 EPEx-positive and T2 or T3 EPEx-negative patients (p=0.088 and p=0.178, respectively). Furthermore, T2 and T3 EPEx-negative patients had similar survival to each other (p=0.877), and distinctly superior survival compared to T2 and T3 EPEx-positive patients (p<0.001). CONCLUSIONS:EPEx was an important prognostic factor in the overall cohort and in differentiating between T stages. This study strongly suggests that staging systems should reinstate EPEx and apply it to all T-stages, especially in T1, where EPEx was absent in 36% of patients.
PMID: 37848688
ISSN: 1873-4626
CID: 5786972

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma

Wasko, Urszula N; Jiang, Jingjing; Curiel-Garcia, Alvaro; Wang, Yingyun; Lee, Bianca; Orlen, Margo; Drizyte-Miller, Kristina; Menard, Marie; Dilly, Julien; Sastra, Stephen A; Palermo, Carmine F; Dalton, Tanner; Hasselluhn, Marie C; Decker-Farrell, Amanda R; Chang, Stephanie; Jiang, Lingyan; Wei, Xing; Yang, Yu C; Helland, Ciara; Courtney, Haley; Gindin, Yevgeniy; Zhao, Ruiping; Kemp, Samantha B; Clendenin, Cynthia; Sor, Rina; Vostrejs, Will; Amparo, Amber A; Hibshman, Priya S; Rees, Matthew G; Ronan, Melissa M; Roth, Jennifer A; Bakir, Basil; Badgley, Michael A; Chabot, John A; Kluger, Michael D; Manji, Gulam A; Quintana, Elsa; Wang, Zhengping; Smith, Jacqueline A M; Holderfield, Matthew; Wildes, David; Aguirre, Andrew J; Der, Channing J; Vonderheide, Robert H; Stanger, Ben Z; Singh, Mallika; Olive, Kenneth P
Broad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations. However, the impact of inhibiting RAS functions in normal tissues is not known. RMC-7977 is a highly selective inhibitor of the active (GTP-bound) forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants. As >90% of human pancreatic ductal adenocarcinoma (PDAC) cases are driven by activating mutations in KRAS, we assessed the therapeutic potential of RMC-7977 in a comprehensive range of PDAC models, including human and murine cell lines, human patient-derived organoids, human PDAC explants, subcutaneous and orthotopic cell-line or patient derived xenografts, syngeneic allografts, and genetically engineered mouse models. We observed broad and pronounced anti-tumor activity across these models following direct RAS inhibition at doses and concentrations that were well-tolerated in vivo. Pharmacological analyses revealed divergent responses to RMC-7977 in tumor versus normal tissues. Treated tumors exhibited waves of apoptosis along with sustained proliferative arrest whereas normal tissues underwent only transient decreases in proliferation, with no evidence of apoptosis. Together, these data establish a strong preclinical rationale for the use of broad-spectrum RAS inhibition in the setting of PDAC.
PMCID:10723304
PMID: 38105998
ISSN: 2692-8205
CID: 5786982

Development, validation, and comparison of a nomogram based on radiologic findings for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: An international multicenter study

Kim, Hyeong Seok; Song, Wookyeong; Choo, Wonho; Lee, Sungyoung; Han, Youngmin; Bassi, Claudio; Salvia, Roberto; Marchegiani, Giovanni; Wolfgang, Christopher L; He, Jin; Blair, Alex B; Kluger, Michael D; Su, Gloria H; Kim, Song Cheol; Song, Ki-Byung; Yamamoto, Masakazu; Hatori, Takashi; Yang, Ching-Yao; Yamaue, Hiroki; Hirono, Seiko; Satoi, Sohei; Fujii, Tsutomu; Hirano, Satoshi; Lou, Wenhui; Hashimoto, Yasushi; Shimizu, Yasuhiro; Del Chiaro, Marco; Valente, Roberto; Lohr, Matthias; Choi, Dong Wook; Choi, Seong Ho; Heo, Jin Seok; Motoi, Fuyuhiko; Matsumoto, Ippei; Lee, Woo Jung; Kang, Chang Moo; Shyr, Yi-Ming; Wang, Shin-E; Han, Ho-Seong; Yoon, Yoo-Seok; Besselink, Marc G; van Huijgevoort, Nadine C M; Sho, Masayuki; Nagano, Hiroaki; Kim, Sang Geol; Honda, Goro; Yang, Yinmo; Yu, Hee Chul; Yang, Jae Do; Chung, Jun Chul; Nagakawa, Yuichi; Seo, Hyung Il; Lee, Seungyeoun; Kim, Hongbeom; Kwon, Wooil; Park, Taesung; Jang, Jin-Young
BACKGROUND:Although we previously proposed a nomogram to predict malignancy in intraductal papillary mucinous neoplasms (IPMN) and validated it in an external cohort, its application is challenging without data on tumor markers. Moreover, existing nomograms have not been compared. This study aimed to develop a nomogram based on radiologic findings and to compare its performance with previously proposed American and Korean/Japanese nomograms. METHODS:We recruited 3708 patients who underwent surgical resection at 31 tertiary institutions in eight countries, and patients with main pancreatic duct >10 mm were excluded. To construct the nomogram, 2606 patients were randomly allocated 1:1 into training and internal validation sets, and area under the receiver operating characteristics curve (AUC) was calculated using 10-fold cross validation by exhaustive search. This nomogram was then validated and compared to the American and Korean/Japanese nomograms using 1102 patients. RESULTS:Among the 2606 patients, 90 had main-duct type, 900 had branch-duct type, and 1616 had mixed-type IPMN. Pathologic results revealed 1628 low-grade dysplasia, 476 high-grade dysplasia, and 502 invasive carcinoma. Location, cyst size, duct dilatation, and mural nodule were selected to construct the nomogram. AUC of this nomogram was higher than the American nomogram (0.691 vs 0.664, P = .014) and comparable with the Korean/Japanese nomogram (0.659 vs 0.653, P = .255). CONCLUSIONS:A novel nomogram based on radiologic findings of IPMN is competitive for predicting risk of malignancy. This nomogram would be clinically helpful in circumstances where tumor markers are not available. The nomogram is freely available at http://statgen.snu.ac.kr/software/nomogramIPMN.
PMID: 33811460
ISSN: 1868-6982
CID: 4871112

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma

Gartrell, Robyn D; Enzler, Thomas; Kim, Pan S; Fullerton, Benjamin T; Fazlollahi, Ladan; Chen, Andrew X; Minns, Hanna E; Perni, Subha; Weisberg, Stuart P; Rizk, Emanuelle M; Wang, Samuel; Oh, Eun Jeong; Guo, Xinzheng V; Chiuzan, Codruta; Manji, Gulam A; Bates, Susan E; Chabot, John; Schrope, Beth; Kluger, Michael; Emond, Jean; Rabadán, Raul; Farber, Donna; Remotti, Helen E; Horowitz, David P; Saenger, Yvonne M
Patients with pancreatic ductal adenocarcinoma (PDAC) have a grim prognosis despite complete surgical resection and intense systemic therapies. While immunotherapies have been beneficial with many different types of solid tumors, they have almost uniformly failed in the treatment of PDAC. Understanding how therapies affect the tumor immune microenvironment (TIME) can provide insights for the development of strategies to treat PDAC. We used quantitative multiplexed immunofluorescence (qmIF) quantitative spatial analysis (qSA), and immunogenomic (IG) analysis to analyze formalin-fixed paraffin embedded (FFPE) primary tumor specimens from 44 patients with PDAC including 18 treated with neoadjuvant chemoradiation (CRT) and 26 patients receiving no treatment (NT) and compared them with tissues from 40 treatment-naïve melanoma patients. We find that relative to NT tumors, CD3+ T cell infiltration was increased in CRT treated tumors (p = .0006), including increases in CD3+CD8+ cytotoxic T cells (CTLs, p = .0079), CD3+CD4+FOXP3- T helper cells (Th, p = .0010), and CD3+CD4+FOXP3+ regulatory T cells (Tregs, p = .0089) with no difference in CD68+ macrophages. IG analysis from micro-dissected tissues indicated overexpression of genes involved in antigen presentation, T cell activation, and inflammation in CRT treated tumors. Among treated patients, a higher ratio of Tregs to total T cells was associated with shorter survival time (p = .0121). Despite comparable levels of infiltrating T cells in CRT PDACs to melanoma, PDACs displayed distinct spatial profiles with less T cell clustering as defined by nearest neighbor analysis (p < .001). These findings demonstrate that, while CRT can achieve high T cell densities in PDAC compared to melanoma, phenotype and spatial organization of T cells may limit benefit of T cell infiltration in this immunotherapy-resistant tumor.
PMCID:9090285
PMID: 35558160
ISSN: 2162-402x
CID: 5825862

Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis

He, Dan; Feng, Huijin; Sundberg, Belen; Yang, Jiaxing; Powers, Justin; Christian, Alec H; Wilkinson, John E; Monnin, Cian; Avizonis, Daina; Thomas, Craig J; Friedman, Richard A; Kluger, Michael D; Hollingsworth, Michael A; Grandgenett, Paul M; Klute, Kelsey A; Toste, F Dean; Chang, Christopher J; Chio, Iok In Christine
Cancer mortality is primarily a consequence of its metastatic spread. Here, we report that methionine sulfoxide reductase A (MSRA), which can reduce oxidized methionine residues, acts as a suppressor of pancreatic ductal adenocarcinoma (PDA) metastasis. MSRA expression is decreased in the metastatic tumors of PDA patients, whereas MSRA loss in primary PDA cells promotes migration and invasion. Chemoproteomic profiling of pancreatic organoids revealed that MSRA loss results in the selective oxidation of a methionine residue (M239) in pyruvate kinase M2 (PKM2). Moreover, M239 oxidation sustains PKM2 in an active tetrameric state to promote respiration, migration, and metastasis, whereas pharmacological activation of PKM2 increases cell migration and metastasis in vivo. These results demonstrate that methionine residues can act as reversible redox switches governing distinct signaling outcomes and that the MSRA-PKM2 axis serves as a regulatory nexus between redox biology and cancer metabolism to control tumor metastasis.
PMCID:9391305
PMID: 35752173
ISSN: 1097-4164
CID: 5786872

Perioperative and persistent opioid utilization following pancreatectomy in the United States

Kluger, Michael D; Huang, Yongmei Y; Kuo, Jennifer H; Kwon, Wooil; Thomas, Alexander S; Hershman, Dawn L; Schrope, Beth A; Sugahara, Kazuki N; Chabot, John A; Wright, Jason D
BACKGROUND:Opioids are central to analgesia for pancreatic diseases. Individuals undergoing pancreatectomy have largely been excluded from studies of opioid use, because of malignancy or chronic use. Surgeons need to understand usage patterns, and practices that may incline patients toward persistent post-operative use. METHODS:A retrospective study using IBM Watson Health MarketScan database examined patterns of peri-pancreatectomy opioid use between 2009 and 2017. Patients were grouped by opioid use 12 months to 31 days prior to pancreatectomy and followed for persistent use (refills 90-180 days postoperatively). Morphine milligram equivalents (MME) were calculated. Multivariable models explored associations between clinical characteristics, perioperative use and persistent use. RESULTS:Opioids were used within the year prior to surgery by 35.6% of 8325 patients. The median MME for opioid naïve patients (400 mg) was a fraction of the 1800 mg prescribed to chronic opioid users for peri-operative analgesia. The rate of persistent opioid use was 15.1% among naïve, 27.2% among intermittent and 77.3% among chronic opioid users. Multivariable models demonstrated naïve and intermittent users who filled a prescription within 30 days prior to pancreatectomy, those who were prescribed total MME ≥1500 mg, and a ≥14 day supply were most at risk of persistent opioid use. Almost 23% of chronic users stopped using opioids post-operatively, suggesting surgery can provide relief. CONCLUSION:Preoperative and persistent opioid use after pancreatectomy is substantially greater than expected based on other operations. Providers may mitigate this by recognizing the issue, managing expectations, and altering the timing and quantities of opioids prescribed.
PMID: 34815188
ISSN: 1477-2574
CID: 5786832